Promising prostate cancer combo trial halted early – what it means
NCT ID NCT05009290
First seen Apr 06, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial was stopped early, but researchers were looking at whether the combination led to no cancer remaining in the surgical specimen and longer time without cancer spread. About 391 men were planned to join, but results are not yet available due to early termination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HIGH-RISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER WHO ARE CANDIDATES FOR RADICAL PROSTATECTOMY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.